Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Pharmaceutical Cos.

www.janssen.com

Latest From Janssen Pharmaceutical Cos.

Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio

AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.

Deal Watch Business Strategies

First Phase III IBD Trial Reads Out Positive For Janssen’s Tremfya

The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.

Clinical Trials Gastrointestinal

Long-Term Postmarket Studies For Gene Therapies May Need To Be Combined, Standardized

Running multiple product-specific postmarket trials for 15 years or longer would not be cost-effective and one industry stakeholder suggests workstreams eventually could merge.

Gene Therapy Post Market Regulation & Studies

Korea’s Clinical Trial Landscape In 2022: Approvals Fall To Pre-COVID Levels

The Pink Sheet takes an infographic look at South Korea's clinical trial trends in 2022 to illustrate how the country's biopharma R&D is developing and how activities are recovering in the post-pandemic situation. One key takeaway is that approvals for trial starts have fallen back to pre-COVID levels, suggesting a falling off of activity related to drugs and vaccines for the virus.

South Korea Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register